Telehealth companies are capitalizing on the growing demand for weight loss drugs and are not only treating patients with obesity but also influencing how the medical community approaches obesity. One prominent player in this space, Ro, recently introduced a new questionnaire aimed at measuring “food noise,” a term commonly used by individuals with obesity to describe constant and overwhelming thoughts about food. Developed by academic researchers with funding from Ro, the scale is designed to assess whether treatments can help reduce patients’ level of food noise, a concept that has gained traction with the introduction of new GLP-1 drugs like Wegovy and Zepbound.
Ro is utilizing the scale to monitor patients’ progress during treatment and is also licensing it to pharmaceutical companies for use in clinical trials. By incorporating this tool into their telehealth platform, Ro is not only enhancing patient care but also contributing to the broader understanding of obesity within the medical community.
While the details of Ro’s innovative approach to tackling obesity are intriguing, further insights and in-depth analysis of this topic are available exclusively to STAT+ subscribers. Unlocking this article will provide access to premium content, newsletters, events, and news alerts. Subscription plans for individuals and groups are available, ensuring that valuable information on cutting-edge developments in healthcare is within reach.
For those interested in delving deeper into the transformative impact of telehealth on weight loss treatment and the evolving perception of obesity in the medical field, subscribing to STAT+ is the key to unlocking a wealth of exclusive content. Subscribe today to stay informed and engaged with the latest advancements in healthcare.
